ES
MCID: EWN003
MIFTS: 69

Ewing Sarcoma (ES)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Ewing Sarcoma

MalaCards integrated aliases for Ewing Sarcoma:

Name: Ewing Sarcoma 57 12 53 25 59 74 37 13 15 17
Neuroepithelioma 57 75 53 59 55 72
Ewing's Sarcoma 75 53 25 29 6
Ewing's Tumor 12 53 25 74
Primitive Neuroectodermal Tumor 74 6 17
Ewings Sarcoma 12 55 72
Askin Tumor 74 44 17
Localized Peripheral Primitive Neuroectodermal Tumor 12 72
Ewings Sarcoma-Primitive Neuroectodermal Tumor 12 72
Peripheral Primitive Neuroectodermal Tumor 12 59
Peripheral Neuroepithelioma 74 55
Sarcoma, Ewing's 53 40
Ewing Tumor 53 25
Es 57 74
Localized Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Extraosseous Ewings Sarcoma-Primitive Neuroepithelial Tumor 72
Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Neuroectodermal Tumors, Primitive, Peripheral 44
Neuroectodermal Tumor, Primitive 72
Pnet of Thoracopulmonary Region 12
Ewing's Family Localized Tumor 12
Ewing Sarcoma Family of Tumors 74
Neuroepithelioma, Peripheral 72
Localized Ewing's Sarcoma 12
Tumor of the Ewing Family 25
Extraosseous Ewing Tumor 74
Localized Ewing Sarcoma 12
Localized Ewing's Tumor 12
Ewing Family of Tumors 25
Pnet of the Chest Wall 74
Peripheral Pnet 59
Disorder of Eye 72
Sarcoma, Ewing 44
Askin's Tumor 72
Ppnet 59
Pnet 74
Esft 74
Pne 74

Characteristics:

Orphanet epidemiological data:

59
ewing sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;
neuroepithelioma
Inheritance: Not applicable; Age of onset: Childhood;

HPO:

32
ewing sarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:3369
OMIM 57 612219
KEGG 37 H00035
MESH via Orphanet 45 D018241
UMLS via Orphanet 73 C0027828 C0553580 C0684337
UMLS 72 C0015397 C0206663 C0279980 more

Summaries for Ewing Sarcoma

Genetics Home Reference : 25 Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor. Ewing sarcomas most often occur in children and young adults. Affected individuals usually feel stiffness, pain, swelling, or tenderness of the bone or surrounding tissue. Sometimes, there is a lump near the surface of the skin that feels warm and soft to the touch. Often, children have a fever that does not go away. Ewing sarcoma of bone can cause weakening of the involved bone, and affected individuals may have a broken bone with no obvious cause. It is common for Ewing sarcoma to spread to other parts of the body (metastasize), usually to the lungs, to other bones, or to the bone marrow.

MalaCards based summary : Ewing Sarcoma, also known as neuroepithelioma, is related to intracranial primitive neuroectodermal tumor and primitive neuroectodermal tumor of the cervix uteri, and has symptoms including fever, visual disturbance and eye manifestations. An important gene associated with Ewing Sarcoma is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Chromatin Regulation / Acetylation. The drugs Lenograstim and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and lung, and related phenotypes are peripheral primitive neuroectodermal neoplasm and seizures

Disease Ontology : 12 A bone cancer that has material basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm.

NIH Rare Diseases : 53 Ewing sarcoma is a malignant (cancerous) bone tumor that affects children. It can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. The tumor may arise anywhere in the body, usually in the long bones of the arms and legs, the pelvis, or the chest. It may also develop in the skull or the flat bones of the trunk. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Fever may also be present. The tumor often spreads (metastasis) to the lungs and other bones. The cause of Ewing sarcoma is unknown. Most cases are thought to occur randomly and many involved a reciprocal translocation between chromosomes 11 and 22. Treatment depends upon a number of factors, but may include chemotherapy, radiation and/or surgical interventions.

OMIM : 57 The Ewing sarcoma family of tumors (primitive neuroectodermal tumors; PNET) comprise morphologically heterogeneous tumors that are characterized by nonrandom chromosomal translocations involving the EWS gene on chromosome 22q12 and one of several members of the ETS family of transcription factors. The tumors include Ewing sarcoma, peripheral neuroepithelioma, and Askin tumor. In approximately 90% of cases of ESFT, the FLI1 gene (193067) on chromosome 11 is the fusion partner of EWS; in approximately 10%, the EWS fusion partner is the ERG gene (165080) on chromosome 22. Many other ETS family members have been identified as fusion partners of EWS, but these cases are rare (Khoury, 2005). (612219)

KEGG : 37
Ewing sarcoma is the second most common malignant bone tumor occurring in children and young adults, and accounts for 10-15% of all primary bone tumors. The annual incidence is approximately 0.6/million total population, and it usually occurs between the ages of 10 and 20 years. Ewing's sarcoma is in 85% of cases associated with the translocation t(11;22)(q24;q12), which leads to the formation of the EWSR1-FLI1 fusion gene. In another 10-15% of cases the translocation t(21;12)(22;12) generates the EWSR1-ERG fusion, whereas the remaining 1-5% of cases may harbor one of several possible translocations, each resulting in a fusion gene containing a portion of the EWSR1 gene and a member of the ETS family of transcription factors.

UniProtKB/Swiss-Prot : 74 Ewing sarcoma: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

Wikipedia : 75 Ewing's sarcoma is a type of cancer that forms in bone or soft tissue. Symptoms may include swelling and... more...

Related Diseases for Ewing Sarcoma

Diseases related to Ewing Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1113)
# Related Disease Score Top Affiliating Genes
1 intracranial primitive neuroectodermal tumor 35.4 ENO2 CD99
2 primitive neuroectodermal tumor of the cervix uteri 35.3 PTPRC ENO2
3 extraskeletal ewing sarcoma 34.8 PTPRC FUS FLI1 EWSR1 ERG ENO2
4 askin's tumor 34.0 EWSR1 ENO2
5 sarcoma 32.3 XAGE1B XAGE1A WT1 POU5F1 FUS FLI1
6 small cell osteogenic sarcoma 32.0 EWSR1 ENO2
7 rhabdomyosarcoma 31.9 XAGE1B XAGE1A PTPRC IGF1R EWSR1 ENO2
8 chondrosarcoma 31.8 TAF15 EWSR1 ENO2
9 desmoplastic small round cell tumor 31.8 WT1 EWSR1 ENO2
10 teratoma 31.8 POU5F1 ENO2 CD99
11 olfactory neuroblastoma 31.5 PTPRC EWSR1 ENO2
12 malignant teratoma 31.4 POU5F1 ENO2
13 kidney rhabdoid cancer 31.4 WT1 PTPRC EWSR1 ENO2 CD99
14 vulvar sarcoma 31.4 PTPRC EWSR1
15 cauda equina neoplasm 31.4 WT1 EWSR1 ENO2
16 bladder sarcoma 31.3 EWSR1 CD99
17 rhabdoid cancer 31.3 WT1 EWSR1 ENO2
18 rhabdomyosarcoma 2 31.3 WT1 IGF1R EWSR1 ENO2
19 subependymoma 31.2 NCAM1 ENO2
20 rhabdoid tumor predisposition syndrome 1 31.2 WT1 PTPRC IGF1R
21 small cell carcinoma 31.2 PTPRC NCAM1 ENO2
22 myxoid chondrosarcoma 31.2 TAF15 EWSR1
23 fibrous histiocytoma 31.1 FUS EWSR1 ATF1
24 cellular myxoid liposarcoma 31.1 FUS EWSR1
25 wilms tumor 1 31.1 WT1 IGF1R EWSR1 ENO2
26 extraosseous chondrosarcoma 31.0 TAF15 FUS EWSR1 ENO2
27 muscle cancer 31.0 WT1 EWSR1 ENO2
28 histiocytoma 31.0 PTPRC FUS EWSR1 ATF1
29 malignant mesenchymoma 31.0 WT1 NCAM1 EWSR1
30 myxoid liposarcoma 30.8 IGF1R FUS EWSR1 ATF1
31 chondrosarcoma, extraskeletal myxoid 30.8 WT1 TAF15 FUS EWSR1 ENO2
32 epidural neoplasm 30.8 PTPRC CD99
33 clear cell sarcoma 30.7 WT1 FUS EWSR1 ENO2 ATF1
34 gastrointestinal stromal tumor 30.0 NCAM1 ETV1 ENO2
35 extraosseous ewing sarcoma 12.8
36 cerebral primitive neuroectodermal tumor 12.7
37 ewing sarcoma of bone 12.6
38 primitive neuroectodermal tumor of the corpus uteri 12.5
39 extraosseous ewings sarcoma-primitive neuroepithelial tumor 12.4
40 soft tissue peripheral neuroepithelioma 12.4
41 bone peripheral neuroepithelioma 12.3
42 pancreatic neuroendocrine tumor 12.2
43 dissociative seizures 12.0
44 pineoblastoma 12.0
45 ependymoblastoma 11.8
46 spinal cord primitive neuroectodermal neoplasm 11.8
47 cerebellopontine angle primitive neuroectodermal 11.8
48 supratentorial primitive neuroectodermal tumor 11.7
49 childhood supratentorial embryonal tumor, not otherwise specified 11.6
50 emanuel syndrome 11.5

Graphical network of the top 20 diseases related to Ewing Sarcoma:



Diseases related to Ewing Sarcoma

Symptoms & Phenotypes for Ewing Sarcoma

Human phenotypes related to Ewing Sarcoma:

59 32 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 peripheral primitive neuroectodermal neoplasm 59 32 obligate (100%) Obligate (100%) HP:0030067
2 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
3 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
4 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
5 anemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001903
6 abnormal bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0001892
7 pruritus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000989
8 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
9 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
10 back pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0003418
11 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
12 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
13 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
14 headache 59 32 occasional (7.5%) Occasional (29-5%) HP:0002315
15 episodic abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002574
16 hyporeflexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001265
17 ovarian neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0100615
18 neoplasm of the pancreas 59 32 occasional (7.5%) Occasional (29-5%) HP:0002894
19 abdominal distention 59 32 occasional (7.5%) Occasional (29-5%) HP:0003270
20 torticollis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000473
21 lower limb muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0007340
22 spinal cord tumor 59 32 occasional (7.5%) Occasional (29-5%) HP:0010302
23 metrorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100608
24 uterine neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0010784
25 sensory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0003474
26 abnormality of the scalp 59 32 occasional (7.5%) Occasional (29-5%) HP:0001965
27 elevated carcinoma antigen 125 level 59 32 occasional (7.5%) Occasional (29-5%) HP:0031030
28 pelvic mass 59 32 occasional (7.5%) Occasional (29-5%) HP:0031501
29 upper limb pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0012513
30 brain neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0030692
31 abnormality of the thoracic spine 59 32 occasional (7.5%) Occasional (29-5%) HP:0100711
32 precocious puberty 59 32 very rare (1%) Very rare (<4-1%) HP:0000826
33 increased lactate dehydrogenase activity 59 32 very rare (1%) Very rare (<4-1%) HP:0025435
34 proptosis 59 32 very rare (1%) Very rare (<4-1%) HP:0000520
35 elevated alpha-fetoprotein 59 32 very rare (1%) Very rare (<4-1%) HP:0006254
36 abnormality of the superior cerebellar peduncle 59 32 very rare (1%) Very rare (<4-1%) HP:0011932
37 neoplasm of the scrotum 59 32 very rare (1%) Very rare (<4-1%) HP:0100849
38 ewing sarcoma 32 HP:0012254

Clinical features from OMIM:

612219

UMLS symptoms related to Ewing Sarcoma:


fever, visual disturbance, eye manifestations, pathological conditions, signs and symptoms, redness or discharge of eye, pain in or around eye, lid retraction

MGI Mouse Phenotypes related to Ewing Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ERG ETV4 FLI1 IGF1R PTPRC WT1

Drugs & Therapeutics for Ewing Sarcoma

Drugs for Ewing Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
leucovorin Approved Phase 3 58-05-9 143 6006
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Donepezil Approved Phase 3 120014-06-4 3152
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Ondansetron Approved Phase 3 99614-02-5 4595
12 Cranberry Approved, Investigational Phase 3
13 Grape Approved Phase 3
14
Fluorouracil Approved Phase 3 51-21-8 3385
15
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
16
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
17
Daunorubicin Approved Phase 3 20830-81-3 30323
18
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
19
Histamine Approved, Investigational Phase 3 51-45-6 774
20
Cyproheptadine Approved Phase 3 129-03-3 2913
21
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
24
Treosulfan Investigational Phase 3 299-75-2 9296
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
27 Deslorelin Investigational, Vet_approved Phase 2, Phase 3 57773-65-6
28 Diphosphonates Phase 3
29 Adjuvants, Immunologic Phase 3
30 Nucleic Acid Synthesis Inhibitors Phase 3
31 Hormones Phase 3
32 Calcium, Dietary Phase 3
33 Micronutrients Phase 3
34 Nutrients Phase 3
35 Trace Elements Phase 3
36 BB 1101 Phase 3
37 Antidotes Phase 3
38 Anesthetics, Intravenous Phase 3
39 Narcotics Phase 3
40 Analgesics, Opioid Phase 3
41 Adjuvants, Anesthesia Phase 3
42 Anesthetics, General Phase 3
43 Antiemetics Phase 3
44 Autonomic Agents Phase 3
45 Folic Acid Antagonists Phase 3
46 Vitamin B9 Phase 3
47 Folate Phase 3
48 Vitamin B Complex Phase 3
49 Nootropic Agents Phase 3
50 Cholinesterase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 410)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
2 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
3 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
4 Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma Unknown status NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
5 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
6 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
7 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
8 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
11 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
12 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children &gt;/= to 8 Months and &lt;3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
13 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
14 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
15 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children &lt;36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
16 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
17 An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR) Recruiting NCT02066220 Phase 2, Phase 3 Reduced-intensity maintenance chemotherapy;Maintenance chemotherapy
18 Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs) Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
19 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
20 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
21 Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. Active, not recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
22 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Active, not recruiting NCT00392327 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate
23 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
24 Assessment of the Effect of a Co-treatment With GnRH Analogs on the Ovarian Reserve in Adolescents and Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
25 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
26 Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules Terminated NCT00751920 Phase 3
27 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
28 Post-operative Radiotherapy Randomization in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
29 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
30 Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
31 Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
32 High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors. Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
33 Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
34 Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin Unknown status NCT02687958 Phase 2 Everolimus
35 Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours Unknown status NCT00274911 Phase 2 cisplatin;lomustine;vincristine sulfate
36 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
37 Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy Unknown status NCT00180791 Phase 2 Etoposide, carboplatin, melphalan, cisplatin, thiotepa
38 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
39 A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter Unknown status NCT02928575 Phase 2 Sunitinib;Temozolomide
40 A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours Unknown status NCT03216148 Phase 2
41 Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T) Unknown status NCT02188550 Phase 2 everolimus and letrozole
42 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
43 A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT) Completed NCT00055952 Phase 2 exatecan mesylate
44 Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
45 A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease Completed NCT00006234 Phase 1, Phase 2
46 Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma Completed NCT00470275 Phase 2 cytarabine
47 Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
48 A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma Completed NCT00330421 Phase 2 sorafenib tosylate
49 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
50 Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewing's Sarcoma, Osteosarcoma, Or Unresectable Or Locally Recurrent Chondrosarcoma [SARC Study] Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Ewing Sarcoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyclophosphamide
Cyclophosphamide
Dactinomycin
Docetaxel
Etoposide
Etoposide
etoposide phosphate
Ifosfamide
Irinotecan
Prednisone
PREDNISONE PWDR
Topotecan
Vincristine

Cochrane evidence based reviews: sarcoma, ewing

Genetic Tests for Ewing Sarcoma

Genetic tests related to Ewing Sarcoma:

# Genetic test Affiliating Genes
1 Ewing's Sarcoma 29 EWSR1

Anatomical Context for Ewing Sarcoma

MalaCards organs/tissues related to Ewing Sarcoma:

41
Bone, Brain, Lung, Bone Marrow, T Cells, Eye, Testes

Publications for Ewing Sarcoma

Articles related to Ewing Sarcoma:

(show top 50) (show all 3595)
# Title Authors PMID Year
1
Ewing sarcoma family of tumors. 9 38 8
16096383 2005
2
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. 38 8
29513652 2018
3
Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. 38 8
17661343 2007
4
Esthesioneuroblastoma is not a member of the primitive peripheral neuroectodermal tumour-Ewing's group. 38 8
10574242 1999
5
A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. 9 8
7700648 1995
6
The neuroepithelioma breakpoint on chromosome 22 is proximal to the meningioma locus. 38 8
2303258 1990
7
Comparative mapping of the constitutional and tumor-associated 11;22 translocations. 38 8
2741943 1989
8
Translocation t(11;22) in esthesioneuroblastoma. 38 8
3478125 1987
9
Comparison of constitutional and tumor-associated 11;22 translocations: nonidentical breakpoints on chromosomes 11 and 22. 38 8
3461479 1986
10
Cytogenetic characterization of selected small round cell tumors of childhood. 38 8
3004699 1986
11
Translocation of oncogene c-sis from chromosome 22 to chromosome 11 in a Ewing sarcoma-derived cell line. 38 8
2983195 1985
12
Chromosome translocation in peripheral neuroepithelioma. 38 8
6749231 1984
13
A patient with two Ewing's sarcomas with distinct EWS fusion transcripts. 8
15044653 2004
14
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. 8
10561219 1999
15
Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. 8
10197607 1999
16
EWS-FLI1 fusion transcripts identified in patients with typical neuroblastoma. 8
9135495 1997
17
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. 8
9005992 1997
18
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. 8
1695726 1990
19
Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). 8
3163261 1988
20
Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). 8
3163262 1988
21
t(11;22) and other chromosomal rearrangements in Ewing's sarcoma. 8
3467113 1986
22
Chromosomal abnormalities in secondary Ewing's sarcoma. 8
6148551 1984
23
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). 8
6713356 1984
24
Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. 8
6713357 1984
25
Neuroblastoma and the differential diagnosis of small-, round-, blue-cell tumors. 8
6345338 1983
26
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. 9 38
20526094 2010
27
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. 9 38
20197394 2010
28
Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. 9 38
19725831 2010
29
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. 9 38
20332468 2010
30
Specificity of fusion genes in adipocytic tumors. 9 38
20332486 2010
31
Identification of a tripartite import signal in the Ewing Sarcoma protein (EWS). 9 38
19879242 2009
32
Diagnostic utility of nestin expression in pediatric tumors in the region of the kidney. 9 38
19417621 2009
33
Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. 9 38
19840522 2009
34
Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall. 9 38
19349856 2009
35
Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. 9 38
19491900 2009
36
Ewing's sarcoma: standard and experimental treatment options. 9 38
19533369 2009
37
Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis. 9 38
19124484 2009
38
Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. 9 38
18677114 2008
39
A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. 9 38
18676850 2008
40
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. 9 38
18504440 2008
41
A comparative immunohistochemical analysis of small round cell tumors of childhood: utility of peripherin and alpha-internexin as markers for neuroblastomas. 9 38
18528283 2008
42
The Ewing sarcoma protein (EWS) binds directly to the proximal elements of the macrophage-specific promoter of the CSF-1 receptor (csf1r) gene. 9 38
18453593 2008
43
The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells. 9 38
18347058 2008
44
Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. 9 38
18413612 2008
45
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. 9 38
17262795 2008
46
Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. 9 38
17912356 2007
47
Expression of MYCN in pediatric synovial sarcoma. 9 38
17464317 2007
48
Evidence for a role of glycosphingolipids in CXCR4-dependent cell migration. 9 38
17511990 2007
49
Primary Ewing sarcoma of the brain: a case report and literature review. 9 38
17525681 2007
50
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. 9 38
17334346 2007

Variations for Ewing Sarcoma

ClinVar genetic disease variations for Ewing Sarcoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 BAP1 NM_004656.4(BAP1): c.256-3C> A single nucleotide variant Conflicting interpretations of pathogenicity rs752536342 3:52442096-52442096 3:52408080-52408080
2 TSC1 NM_000368.4(TSC1): c.1460C> G (p.Ser487Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs118203532 9:135781505-135781505 9:132906118-132906118
3 CDK4 NM_000075.4(CDK4): c.776C> T (p.Ser259Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs201617914 12:58143008-58143008 12:57749225-57749225

Cosmic variations for Ewing Sarcoma:

9 (show all 47)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43687 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 9
2 COSM11333 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 9
3 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 9
4 COSM4774989 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 9
5 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 9
6 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 9
7 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 9
8 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
9 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 9
10 COSM6954536 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 9
11 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 9
12 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 9
13 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
14 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 9
15 COSM1732355 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 9
16 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 9
17 COSM3908208 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 9
18 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
19 COSM2923082 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 9
20 COSM3908209 soft tissue,bone,sarcoma,NS c.355C>T p.R119* 9:77815650-77815650 9
21 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 9
22 COSM1640840 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 9
23 COSM307279 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 9
24 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
25 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 9
26 COSM2744872 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 9
27 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 9
28 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 9
29 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
30 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 9
31 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 9
32 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 9
33 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
34 COSM3937613 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 9
35 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 9
36 COSM307282 soft tissue,upper leg,sarcoma,NS c.362A>G p.H121R 17:7674890-7674890 9
37 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 9
38 COSM121082 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 9
39 COSM121084 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 9
40 COSM121083 soft tissue,upper leg,sarcoma,NS c.220C>T p.Q74* 17:7675113-7675113 9
41 COSM3388198 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 9
42 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 9
43 COSM121081 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 9
44 COSM307280 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 9
45 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 9
46 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 9
47 COSM307281 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 9

Copy number variations for Ewing Sarcoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13324 1 1 124300000 Deletion Ewing''s sarcoma
2 13741 1 1 27800000 Deletion Ewing''s sarcoma
3 16432 1 124300000 247249719 Gain Ewing''s sarcoma
4 16433 1 124300000 247249719 Gain Ewing''s sarcoma
5 16640 1 1286916 1536363 Loss Ewing''s sarcoma
6 17338 1 142400000 247249719 Gain Ewing''s sarcoma
7 17361 1 142565191 158296814 Gain AG1 Ewing''s sarcoma
8 20077 1 15300000 154800000 Gain Ewing''s sarcoma
9 20877 1 154978607 154979115 Gain HDGF Ewing''s sarcoma
10 21389 1 158408551 189951958 Gain FREB Ewing''s sarcoma
11 27410 1 208096981 208097464 Gain C1orf107 Ewing''s sarcoma
12 27922 1 215848737 215849264 Copy number GPATCH2 Ewing''s sarcoma
13 28256 1 220611046 220683633 Loss FBXO28 Ewing''s sarcoma
14 28623 1 224110806 224111244 Gain TMEM63A Ewing''s sarcoma
15 29204 1 228895774 228896323 Gain COG2 Ewing''s sarcoma
16 29247 1 229426179 229426672 Copy number C1orf131 Ewing''s sarcoma
17 29294 1 2300000 27800000 Deletion Ewing''s sarcoma
18 29735 1 234815741 234816376 Gain HEATR1 Ewing''s sarcoma
19 31804 1 3118000 5001000 Deletion Ewing''s sarcoma
20 31805 1 3118000 5001000 Deletion Ewing''s sarcoma
21 34220 1 53642491 53911866 Loss DMRTB1 Ewing''s sarcoma
22 35775 1 67181498 104009233 Loss SLC35D1 Ewing''s sarcoma
23 37996 1 9778925 10706826 Deletion APITD1 Ewing''s sarcoma
24 37997 1 9778925 10706826 Deletion CLSTN1 Ewing''s sarcoma
25 37998 1 9778925 10706826 Deletion CORT Ewing''s sarcoma
26 37999 1 9778925 10706826 Deletion CTNNBIP1 Ewing''s sarcoma
27 38000 1 9778925 10706826 Deletion DFFA Ewing''s sarcoma
28 38001 1 9778925 10706826 Deletion LZIC Ewing''s sarcoma
29 38002 1 9778925 10706826 Deletion NMNAT1 Ewing''s sarcoma
30 38003 1 9778925 10706826 Deletion PEX14 Ewing''s sarcoma
31 38004 1 9778925 10706826 Deletion PGD Ewing''s sarcoma
32 38005 1 9778925 10706826 Deletion RBP7 Ewing''s sarcoma
33 38141 10 1 135374737 Deletion Ewing''s sarcoma
34 41153 10 138206 135293404 Gain Ewing''s sarcoma
35 48491 11 1 52900000 Gain Ewing''s sarcoma
36 55430 11 52900000 134452384 Gain Ewing''s sarcoma
37 59789 11 777331 821974 Loss BM88 Ewing''s sarcoma
38 60445 11 86456481 127953177 Loss Ewing''s sarcoma
39 61420 12 1 132349534 Gain Ewing''s sarcoma
40 61533 12 1 35400000 Gain Ewing''s sarcoma
41 62737 12 111075038 111075556 Gain TRAFD1 Ewing''s sarcoma
42 63302 12 116955326 116955682 Copy number WSB2 Ewing''s sarcoma
43 64487 12 12873623 12874134 Gain DDX47 Ewing''s sarcoma
44 65323 12 1570852 1571348 Copy number FBXL14 Ewing''s sarcoma
45 66228 12 2670999 2671234 Deletion CACNA1C Ewing''s sarcoma
46 67041 12 35400000 132349534 Gain Ewing''s sarcoma
47 67472 12 41121456 41121979 Gain PPHLN1 Ewing''s sarcoma
48 68463 12 49967 52715434 Gain IQSEC3 Ewing''s sarcoma
49 68787 12 51501640 51502010 Copy number KRT79 Ewing''s sarcoma
50 69068 12 52981304 57130106 Gain Ewing''s sarcoma

Expression for Ewing Sarcoma

Search GEO for disease gene expression data for Ewing Sarcoma.

Pathways for Ewing Sarcoma

Pathways related to Ewing Sarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 TAF15 FUS EWSR1 ERG
2 11.59 WT1 TAF15 IGF1R FUS FLI1 EWSR1
3 11.46 WT1 POU5F1 NCAM1

GO Terms for Ewing Sarcoma

Biological processes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 WT1 POU5F1 FLI1 ETV4 ETV1 ERG
2 regulation of transcription, DNA-templated GO:0006355 9.65 WT1 TAF15 POU5F1 FUS FLI1 EWSR1
3 transcription by RNA polymerase II GO:0006366 8.8 TAF15 POU5F1 ETV1

Molecular functions related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.91 WT1 TAF15 POU5F1 FUS FLI1 ETV4
2 protein binding GO:0005515 9.91 XAGE1B XAGE1A WT1 TAF15 PTPRC POU5F1
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.87 WT1 POU5F1 FLI1 ETV4 ETV1 ERG
4 DNA-binding transcription factor activity GO:0003700 9.7 WT1 POU5F1 FLI1 ETV4 ETV1 ERG
5 sequence-specific DNA binding GO:0043565 9.17 WT1 POU5F1 FLI1 ETV4 ETV1 ERG

Sources for Ewing Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....